Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC. Modest DP, et al. Among authors: knittelfelder r. Anticancer Drugs. 2012 Jul;23(6):666-73. doi: 10.1097/CAD.0b013e328352ff1d. Anticancer Drugs. 2012. PMID: 22441566 Clinical Trial.
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z, Knittelfelder R, Kirchner T, Heinemann V, Zielinski CC. Modest DP, et al. Among authors: knittelfelder r. Oncology. 2012;83(5):241-7. doi: 10.1159/000339534. Epub 2012 Aug 29. Oncology. 2012. PMID: 22948721 Free article.
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T. Kaczirek K, et al. Among authors: knittelfelder r. Clin Colorectal Cancer. 2015 Jun;14(2):91-8. doi: 10.1016/j.clcc.2014.12.003. Epub 2014 Dec 24. Clin Colorectal Cancer. 2015. PMID: 25666295 Clinical Trial.
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Thallinger C, Lang I, Kuhar CG, Bartsch R, Singer CF, Petruzelka L, Melichar B, Knittelfelder R, Brodowicz T, Zielinski C. Thallinger C, et al. Among authors: knittelfelder r. BMC Cancer. 2016 Feb 18;16:121. doi: 10.1186/s12885-016-2171-y. BMC Cancer. 2016. PMID: 26887956 Free PMC article. Clinical Trial.
Mimotope vaccination--from allergy to cancer.
Knittelfelder R, Riemer AB, Jensen-Jarolim E. Knittelfelder R, et al. Expert Opin Biol Ther. 2009 Apr;9(4):493-506. doi: 10.1517/14712590902870386. Expert Opin Biol Ther. 2009. PMID: 19344285 Free PMC article. Review.
Characterization of intrinsic and extrinsic risk factors for celery allergy in immunosenescence.
Untersmayr E, Diesner SC, Brämswig KH, Knittelfelder R, Bakos N, Gundacker C, Lukschal A, Wallmann J, Szalai K, Pali-Schöll I, Boltz-Nitulescu G, Scheiner O, Duschl A, Jensen-Jarolim E. Untersmayr E, et al. Among authors: knittelfelder r. Mech Ageing Dev. 2008 Mar;129(3):120-8. doi: 10.1016/j.mad.2007.10.015. Epub 2007 Nov 13. Mech Ageing Dev. 2008. PMID: 18083215
17 results